tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Naito M et al. Reversal of multidrug resistance by an immunosuppressive agent FK-506. 1992 Cancer Chemother. Pharmacol. pmid:1370765
Yem AW et al. The Hsp56 component of steroid receptor complexes binds to immobilized FK506 and shows homology to FKBP-12 and FKBP-13. 1992 J. Biol. Chem. pmid:1371107
Park ST et al. PPIase catalysis by human FK506-binding protein proceeds through a conformational twist mechanism. 1992 J. Biol. Chem. pmid:1371117
Bishop DK and Li W Cyclosporin A and FK506 mediate differential effects on T cell activation in vivo. 1992 J. Immunol. pmid:1371128
Hatfield SM and Roehm NW Cyclosporine and FK506 inhibition of murine mast cell cytokine production. 1992 J. Pharmacol. Exp. Ther. pmid:1371158
Takaya S et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. 1992 Transplantation pmid:1371195
Francavilla A et al. Inhibition of liver, kidney, and intestine regeneration by rapamycin. 1992 Transplantation pmid:1371198
Matsukawa W et al. Effects of a new immunosuppressive agent, FK506, in rats with active Heymann nephritis. 1992 J. Lab. Clin. Med. pmid:1371298
Sampson BA and Gotschlich EC Neisseria meningitidis encodes an FK506-inhibitable rotamase. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1371354
Andersson J et al. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. 1992 Immunology pmid:1371491
Strasser S et al. Effect of FK506 on insulin secretion in normal dogs. 1992 Metab. Clin. Exp. pmid:1371575
Andersson J et al. FK 506 and cyclosporine inhibit antigen- or mitogen-induced monokine and lymphokine production in vitro. 1992 Transplant. Proc. pmid:1371621
Matsuura T et al. Blockade of interleukin-2 production from cloned T cells by cyclosporine and FK 506 assessed by proliferation assays in vitro. 1992 Transplant. Proc. pmid:1371623
Okamura N et al. Enhanced liver regeneration by FK 506 can be blocked by interleukin-1 alpha and interleukin-2. 1992 Transplant. Proc. pmid:1371624
Matsuzaki T et al. Liver transplantation for diethylnitrosamine-induced hepatocellular carcinoma in rats. 1992 Transplant. Proc. pmid:1373547
Vincent SH et al. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. 1992 Arch. Biochem. Biophys. pmid:1373595
Liu J et al. Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. 1992 Biochemistry pmid:1373650
Adachi A et al. Immunosuppressive effect of FK506 on experimental allergic neuritis in Lewis rats: change of T cell subsets. 1992 Intern. Med. pmid:1373661
Fruman DA et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1373887
Lake JR et al. Maintenance immunosuppression after liver transplantation. 1992 Semin. Liver Dis. pmid:1373916
Taormina D et al. Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers. 1992 Am J Hosp Pharm pmid:1373936
Ochiai T [Advances in the fundamentals and therapeutic use of immunosuppressive agents]. 1992 Arerugi pmid:1374229
Yamada K et al. New morphological changes induced by FK506 in a short period in the rat kidney and the effect of superoxide dismutase and OKY-046 on THEM: the relationship of FK506 nephrotoxicity to lipid peroxidation and change in production of thromboxane A2 in the kidney. 1992 Transpl. Int. pmid:14621878
Hung DT and Schreiber SL cDNA cloning of a human 25 kDa FK506 and rapamycin binding protein. 1992 Biochem. Biophys. Res. Commun. pmid:1374240
Jayaraman T et al. FK506 binding protein associated with the calcium release channel (ryanodine receptor). 1992 J. Biol. Chem. pmid:1374404
Höllsberg P et al. Characterization of HTLV-I in vivo infected T cell clones. IL-2-independent growth of nontransformed T cells. 1992 J. Immunol. pmid:1374452
Schreiber SL and Crabtree GR The mechanism of action of cyclosporin A and FK506. 1992 Immunol. Today pmid:1374612
Demetris AJ et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. 1992 Transplantation pmid:1374944
Chen TS et al. Microbial transformation of immunosuppressive compounds. II. Specific desmethylation of 13-methoxy group of FK 506 and FR 900520 by an unidentified Actinomycete ATCC 53828 [corrected]. 1992 J. Antibiot. pmid:1375593
Meingassner JG and Stütz A Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? 1992 J. Invest. Dermatol. pmid:1375617
Schneck FX et al. Pediatric renal transplantation under FK-506 immunosuppression. 1992 J. Urol. pmid:1375663
Connelly PR and Thomson JA Heat capacity changes and hydrophobic interactions in the binding of FK506 and rapamycin to the FK506 binding protein. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1375751
Lancaster JR et al. EPR detection of heme and nonheme iron-containing protein nitrosylation by nitric oxide during rejection of rat heart allograft. 1992 J. Biol. Chem. pmid:1375934
Hirai T et al. The immunosuppressive effect of FK 506 on canine lung transplantation. 1992 J. Thorac. Cardiovasc. Surg. pmid:1375967
Tai PK et al. Association of a 59-kilodalton immunophilin with the glucocorticoid receptor complex. 1992 Science pmid:1376003
Jegasothy BV et al. Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. 1992 Arch Dermatol pmid:1376102
Wiederrecht G et al. Isolation of a human cDNA encoding a 25 kDa FK-506 and rapamycin binding protein. 1992 Biochem. Biophys. Res. Commun. pmid:1376117
Bernstein L and Daviss SR Organic anxiety disorder with symptoms of akathisia in a patient treated with the immunosuppressant FK506. 1992 Gen Hosp Psychiatry pmid:1376291
Hatfield SM et al. Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists. 1992 J. Pharmacol. Exp. Ther. pmid:1376361
Ericzon BG et al. The effect of FK506 treatment on pancreaticoduodenal allotransplantation in the primate. 1992 Transplantation pmid:1376501
Tze WJ et al. FK 506--an effective immunosuppressant in achieving long-term functional islet allograft survival in diabetic rats. 1992 Transplant. Proc. pmid:1376509
O'Keefe SJ et al. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. 1992 Nature pmid:1377361
Clipstone NA and Crabtree GR Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. 1992 Nature pmid:1377362
Hasegawa S et al. Combination use of suboptimal dose of FK 506 and cyclosporine in canine lung transplantation. 1992 J. Thorac. Cardiovasc. Surg. pmid:1279319
Peattie DA et al. Expression and characterization of human FKBP52, an immunophilin that associates with the 90-kDa heat shock protein and is a component of steroid receptor complexes. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1279700
Lhoëst G et al. Isolation and mass spectrometric identification of two metabolites of FK 506 from rat liver microsomal incubation media. 1992 Pharm Acta Helv pmid:1279730
Benigni A et al. The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. 1992 Transplantation pmid:1279848
Mor E et al. Late-onset acute rejection in orthotopic liver transplantation--associated risk factors and outcome. 1992 Transplantation pmid:1279849
Hirano Y et al. The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. 1992 Transplantation pmid:1279850
Takaya S et al. Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. 1992 Transplantation pmid:1279851
Partaledis JA et al. Saccharomyces cerevisiae contains a homolog of human FKBP-13, a membrane-associated FK506/rapamycin binding protein. 1992 Yeast pmid:1279908
Ozawa K et al. An appraisal of pediatric liver transplantation from living relatives. Initial clinical experiences in 20 pediatric liver transplantations from living relatives as donors. 1992 Ann. Surg. pmid:1280074
Akutsu I et al. [Inhibitory effects of cyclosporin A and FK-506 on eosinophil chemotactic factor activity in culture supernatants of mononuclear cells from asthmatics]. 1992 Arerugi pmid:1280086
Bergstrand H and Lundquist B Human basophil histamine release is differently affected by inhibitors of calmodulin, diacylglycerol kinase and peptidyl prolyl cis-trans isomerase in a secretagogue specific manner. 1992 Allergy pmid:1280915
Barry JM Immunosuppressive drugs in renal transplantation. A review of the regimens. 1992 Drugs pmid:1281071
Min DI et al. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. 1992 Am J Hosp Pharm pmid:1282779
Mochizuki M [Immunotherapy in ocular diseases]. 1992 Nippon Ganka Gakkai Zasshi pmid:1283052
Olejniczak ET et al. A 4D HCCH-TOCSY experiment for assigning the side chain 1H and 13C resonances of proteins. 1992 J. Biomol. NMR pmid:1283353
Bauer S et al. The effect of the new immunosuppressive drug FK506 on the formation of secondary metabolites of cyclosporin A. 1992 Int J Clin Pharmacol Ther Toxicol pmid:1283385
Renoir JM et al. [Effect of immunosuppressants FK506 and rapamycin on the function of progesterone receptor: protein "p59-HBI", intersection between immunology and endocrinology?]. 1992 C. R. Acad. Sci. III, Sci. Vie pmid:1284044
Natazuka T FK506 reverses adriamycin resistance in a multidrug-resistant human leukemia cell line. 1992 Kobe J Med Sci pmid:1284834
Tocci MJ and Sigal NH Recent advances in the mechanism of action of cyclosporine and FK506. 1992 Curr. Opin. Nephrol. Hypertens. pmid:1285380
Bavandi A et al. Diet-induced dermatitis response of hairless rats to systemic treatment with cyclosporin A (Sandimmun), cyclosporin H and FK506. 1992 Exp. Dermatol. pmid:1285411
High KP and Handschumacher RE Immunity, microbial pathogenesis, and immunophilins: finding the keys, now where are the locks? 1992 Infect Agents Dis pmid:1285413
Akutsu I et al. [Inhibitory effect of inhaled FK-506 on increased bronchial responsiveness and eosinophil infiltration in the airway mucosa]. 1992 Arerugi pmid:1377905
Takaori K et al. A comparative study on immunosuppressive effects of cyclosporin A and FK 506 on peripheral blood lymphocytes in dogs. 1992 Biotherapy pmid:1377926
Murthy JN et al. Radioreceptor assay for quantifying FK-506 immunosuppressant in whole blood. 1992 Clin. Chem. pmid:1377995
First MR Renal transplantation for the nephrologist: new immunosuppressive drugs. 1992 Am. J. Kidney Dis. pmid:1371201
Wada H et al. Combination use of suboptimal doses of FK 506 and cyclosporine in canine lung transplantation. 1992 Transplant. Proc. pmid:1379758
Cai X et al. Low-dose of FK 506 and associated blood levels in allotransplantation of rat liver, heart, and skin. 1992 Transplant. Proc. pmid:1379759
Taki J et al. DNA analysis of peripheral blood mononuclear cells for early detection of hepatic graft rejection. 1992 Transplant. Proc. pmid:1379760
Sato Y et al. FK 506 suppresses class II antigen expression in regenerating livers following partial hepatectomy in the rat. 1992 Transplant. Proc. pmid:1379761
Stütz A Immunosuppressive macrolides. 1992 Transplant. Proc. pmid:1379762
Leiva MC and Lyttle CR Leukocyte chemotactic activity of FKBP and inhibition by FK506. 1992 Biochem. Biophys. Res. Commun. pmid:1379802
Iwasaki K et al. Effect of repeated oral doses of a novel immunosuppressive macrolide lactone on hepatic mixed-function oxidase system in the rat. Comparative study with ciclosporin. 1992 Arzneimittelforschung pmid:1379812
Takada K et al. Distribution kinetics of FK-506, a novel immunosuppressant, after intravenous administration to rats in comparison with cyclosporin A. 1992 Biopharm Drug Dispos pmid:1379839
Kahan BD Cyclosporin A, FK506, rapamycin: the use of a quantitative analytic tool to discriminate immunosuppressive drug interactions. 1992 J. Am. Soc. Nephrol. pmid:1379841
Lauerma AI et al. Inhibition of contact allergy reactions by topical FK506. 1992 Lancet pmid:1380111
Steiner JP et al. High brain densities of the immunophilin FKBP colocalized with calcineurin. 1992 Nature pmid:1380130
Aperia A et al. Calcineurin mediates alpha-adrenergic stimulation of Na+,K(+)-ATPase activity in renal tubule cells. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1380157
Nielsen JB et al. Yeast FKBP-13 is a membrane-associated FK506-binding protein encoded by the nonessential gene FKB2. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1380159
Pahl A and Keller U FK-506-binding proteins from streptomycetes producing immunosuppressive macrolactones of the FK-506 type. 1992 J. Bacteriol. pmid:1381710
Takahashi N [Cyclophilin and FK506-binding protein]. 1992 Seikagaku pmid:1381737
Lee TK et al. Mucosal glutamine utilization after small-bowel transplantation: an electrophysiologic study. 1992 J. Surg. Res. pmid:1382152
Kaye RE et al. Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1382293
Edalji R et al. High-level expression of recombinant human FK-binding protein from a fusion precursor. 1992 J. Protein Chem. pmid:1382438
Thomson AW and Starzl TE FK 506 and autoimmune disease: perspective and prospects. 1992 Autoimmunity pmid:1382646
Christians U et al. Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients. 1992 Clin. Chem. pmid:1382896
Fruman DA et al. Correlation of calcineurin phosphatase activity and programmed cell death in murine T cell hybridomas. 1992 Eur. J. Immunol. pmid:1382988
Mittrücker HW and Fleischer B Functional localization of an exocytosis-triggering G-protein in human cytotoxic T lymphocytes. 1992 Immunology pmid:1383135
Yasutomi D et al. Inhibition of programmed cell death by cyclosporin A; preferential blocking of cell death induced by signals via TCR/CD3 complex and its mode of action. 1992 Immunology pmid:1383138
Ruff VA et al. Tissue distribution and cellular localization of hsp56, an FK506-binding protein. Characterization using a highly specific polyclonal antibody. 1992 J. Biol. Chem. pmid:1383222
Wiederrecht G et al. Characterization of high molecular weight FK-506 binding activities reveals a novel FK-506-binding protein as well as a protein complex. 1992 J. Biol. Chem. pmid:1383226
Morris RE Immunopharmacology of new xenobiotic immunosuppressive molecules. 1992 Semin. Nephrol. pmid:1384096
Hendey B et al. Inhibition of neutrophil chemokinesis on vitronectin by inhibitors of calcineurin. 1992 Science pmid:1384129
Chung J et al. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. 1992 Cell pmid:1377606
Xu RX et al. Stereospecific assignments and chi 1 rotamers for FKBP when bound to ascomycin from 3JH alpha,H beta and 3HN,H beta coupling constants. 1992 FEBS Lett. pmid:1377648
Petros AM et al. NMR studies of an FK-506 analog, [U-13C]ascomycin, bound to FK-506-binding protein. 1992 J. Med. Chem. pmid:1377749
Strom TB Molecular immunology and immunopharmacology of allograft rejection. 1992 Kidney Int. Suppl. pmid:1383599
Wang SC et al. FK-506 inhibits proliferation and IL-4 messenger RNA production by a T-helper 2 cell line. 1992 J. Surg. Res. pmid:1383612